MGRX
Mangoceuticals, Inc.1.2000
+0.0600+5.26%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
16.69MP/E (TTM)
-Basic EPS (TTM)
-2.72Dividend Yield
0%Recent Filings
8-K
Mango DAT partners with Cube
Mangoceuticals' subsidiary Mango DAT inked a Master Services Agreement with Cube Operations on December 17, 2025, granting Cube discretionary control over Solana token management via its MPC Wallet platform. Fees tier from 30 bps on AUM under $10M to 10 bps above $250M, plus a 2% execution fee on deposits and $2,500 monthly minimum. Cube handles custody and trades; Mango DAT secures keys. Ties to press release touting up-to-$100M Solana treasury, yet funding not guaranteed.
8-K
MGRX prices $2.5M offering
Mangoceuticals priced a $2.5M registered direct offering on December 18, 2025, selling 1,430,502 common shares at $1.295 and 500,000 pre-funded warrants at $1.29499 to an institutional investor, paired with private warrants for 1,930,502 shares at $1.4245 exercisable over five years. Net proceeds target working capital amid ownership caps at 4.99% or 9.99%. Cash bolsters runway, but dilution looms.
8-K
Borrowed $75K from CEO's trust
Mangoceuticals borrowed $75,000 from The Tiger Cub Trust, controlled by CEO Jacob Cohen, via promissory note dated December 4, 2025. It carries 18% annual interest, compounded monthly, maturing December 4, 2026, or upon default or qualified financing. Prepayments trigger a make-whole premium approximating full-term return. Related-party debt signals tight liquidity.
10-Q
Q3 FY2025 results
Mangoceuticals posted Q3 revenue of $84K, down 37% y/y from $133K yet holding steady q/q while migrating telemedicine platforms. Operating loss hit $7.5M versus $1.8M y/y, driven by $6.6M stock-based comp that dwarfed the $542K salary run-rate; net loss landed at $7.6M or $(0.69) diluted EPS on 11.5M shares, aligning with weighted average. Cash climbed to $481K on $5.2M financing inflows against $4.8M operating burn, leaving $100K related-party debt at quarter-end. Stock compensation exploded.
8-K
Launches GLP-1 programs today
Mangoceuticals clarified its November 13, 2025 press release, launching MangoRx Direct and PeachesRx Direct programs live today. These enable vetted telehealth prescriptions for branded GLP-1s like Zepbound and Wegovy via a third-party provider—no direct Lilly or Novo ties. Programs cost $99/month, excluding meds. Supply hinges on manufacturers.
IPO
Employees
Sector
Industry
BRGX
BioRegenx, Inc
0.02+0.00
GDRX
GoodRx Holdings, Inc.
2.76+0.05
HIMS
Hims & Hers Health, Inc.
36.86+0.61
LFMD
LifeMD, Inc.
3.42+0.15
MAJI
Marijuana Inc.
0.05-0.02
MGRM
Monogram Technologies Inc.
6.00+0.00
MNDR
Mobile-health Network Solutions
1.08+0.02
MRMD
MariMed Inc.
0.12+0.01
TDOC
Teladoc Health, Inc.
7.41+0.07
WGRX
Wellgistics Health, Inc.
0.54-0.04